Brusatol reverses lipopolysaccharide-induced epithelial-mesenchymal transformation and induces apoptosis through PI3K/Akt/NF-кB pathway in human gastric cancer SGC-7901 cells.
Apoptosis
/ drug effects
Biomarkers, Tumor
/ biosynthesis
Cell Line, Tumor
Cell Survival
/ drug effects
Cytokines
/ metabolism
Drug Interactions
Epithelial-Mesenchymal Transition
/ drug effects
Humans
Lipopolysaccharides
/ antagonists & inhibitors
NF-kappa B
/ metabolism
Phosphatidylinositol 3-Kinases
/ metabolism
Proto-Oncogene Proteins c-akt
/ metabolism
Quassins
/ pharmacology
Reactive Oxygen Species
/ metabolism
Signal Transduction
/ drug effects
Stomach Neoplasms
/ drug therapy
Journal
Anti-cancer drugs
ISSN: 1473-5741
Titre abrégé: Anticancer Drugs
Pays: England
ID NLM: 9100823
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
pubmed:
25
11
2020
medline:
15
12
2021
entrez:
24
11
2020
Statut:
ppublish
Résumé
Brusatol is a butyrolactone compound isolated from traditional Chinese medicine Brucea javanica. It has been reported to possess strong cytotoxicity against various cancer cells, thus showing its potential as an anticancer drug. Besides, lipopolysaccharide (LPS) plays a central role in the tumor microenvironment, while epithelial-mesenchymal transformation (EMT), a biological process by which epithelial cells are transformed into mesenchymal phenotypic cells through specific procedures, participates in chronic inflammation and tumor metastasis. This study aimed to investigate the inhibition of LPS-induced tumor cell invasion and metastasis and the molecular mechanism of apoptosis induced by brusatol in human gastric cancer SGC-7901 cells. Cell viability, cell migration and invasion ability, inflammatory factor release, and protein expression were detected using methyl thiazolyl tetrazolium assays, transwell assays, ELISA kit, and Western blot analysis, respectively. The change of EMT marker protein vimentin was assessed using immunofluorescence, while the apoptosis rate was measured using flow cytometry. In summary, brusatol inhibited LPS-induced EMT via the deactivation of the PI3K/Akt/NF-кB signaling pathway. This provides a useful new theoretical basis for the treatment of gastric cancer in the future.
Identifiants
pubmed: 33229902
pii: 00001813-202104000-00005
doi: 10.1097/CAD.0000000000001022
doi:
Substances chimiques
Biomarkers, Tumor
0
Cytokines
0
Lipopolysaccharides
0
NF-kappa B
0
Quassins
0
Reactive Oxygen Species
0
brusatol
14907-98-3
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
394-404Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424.
Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014; 23:700–713.
Choi YJ, Kim N. Gastric cancer and family history. Korean J Intern Med. 2016; 31:1042–1053.
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140:883–899.
Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139:871–890.
Li P, Liu J, Sun J, Duan H. The LPS-pretreated MSCs supply a positive microenvironment for tumor cell proliferation and clone formation. Curr Protein Pept Sci. 2015; 16:295–300.
Zhang D, Li YH, Mi M, Jiang FL, Yue ZG, Sun Y, et al. Modified apple polysaccharides suppress the migration and invasion of colorectal cancer cells induced by lipopolysaccharide. Nutr Res. 2013; 33:839–848.
Cho I-H, Jang EH, Hong D, Jung B, Park M-J, Kim J-H. Suppression of LPS-induced epithelial-mesenchymal transition by aqueous extracts of Prunella vulgaris through inhibition of the NF-kappa B/Snail signaling pathway and regulation of EMT-related protein expression. Oncol Rep. 2015; 34:2445–2450.
Eigebaly SA, Hall IH, Lee KH, Sumida Y, Imakura Y, Wu RY. Antitumor agents. XXXV: effects of brusatol, bruceoside A, and bruceantin on P-388 lymphocytic leukemia cell respiration. J Pharm Sci. 1979; 68:887–890.
Ruifan Y, Ninggao D, Qikuan H, Pengyi G, Yukai X, Qiong Z, et al. Comprehensive anti-tumor effect of Brusatol through inhibition of cell viability and promotion of apoptosis caused by autophagy via the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Biomed Pharmacother. 2018; 105:962–973.
Xiang Y, Ye W, Huang C, Yu D, Chen H, Deng T, et al. Brusatol enhances the chemotherapy efficacy of gemcitabine in pancreatic cancer via the Nrf2 signalling pathway. Oxid Med Cell Longev. 2018; 2018:2360427.
Rich T, Watson CJ, Wyllie A. Apoptosis: the germs of death. Nat Cell Biol. 1999; 1:E69–E71.
Hassan M, Watari H, AbuAlmaaty A, Ohba Y, Sakuragi N. Apoptosis and molecular targeting therapy in cancer. Biomed Res Int. 2014; 2014:150845.
Karimian A, Mir SM, Parsian H, Refieyan S, Mirza-Aghazadeh-Attari M, Yousefi B, Majidinia M. Crosstalk between phosphoinositide 3-kinase/Akt signaling pathway with DNA damage response and oxidative stress in cancer. J Cell Biochem. 2019; 120:10248–10272.
Su LJ, Zhang JH, Gomez H, Murugan R, Hong X, Xu D, et al. Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis. Oxid Med Cell Longev. 2019; 2019:5080843.
Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8:627–644.
Avila-Carrasco L, Majano P, Sánchez-Toméro JA, Selgas R, López-Cabrera M, Aguilera A, González Mateo G. Natural plants compounds as modulators of epithelial-to-mesenchymal transition. Front Pharmacol. 2019; 10:715.
Xiang Y, Ye W, Huang C, Lou B, Zhang J, Yu D, et al. Brusatol inhibits growth and induces apoptosis in pancreatic cancer cells via JNK/p38 MAPK/NF-κb/Stat3/Bcl-2 signaling pathway. Biochem Biophys Res Commun. 2017; 487:820–826.
Yang SW, Ping YF, Jiang YX, Luo X, Zhang X, Bian XW, Yu PW. ATG4A promotes tumor metastasis by inducing the epithelial-mesenchymal transition and stem-like properties in gastric cells. Oncotarget. 2016; 7:39279–39292.
Mannino MH, Zhu Z, Xiao H, Bai Q, Wakefield MR, Fang Y. The paradoxical role of IL-10 in immunity and cancer. Cancer Lett. 2015; 367:103–107.
Oft M. IL-10: master switch from tumor-promoting inflammation to antitumor immunity. Cancer Immunol Res. 2014; 2:194–199.
Jiang YX, Yang SW, Li PA, Luo X, Li ZY, Hao YX, Yu PW. The promotion of the transformation of quiescent gastric cancer stem cells by IL-17 and the underlying mechanisms. Oncogene. 2017; 36:1256–1264.
Yuan Z, Peng LS, Zhao YL, Yun S, Mao XH, Chen W, et al. CD8+ T cells that produce interleukin-17 regulate myeloid-derived suppressor cells and are associated with survival time of patients with gastric cancer. Gastroenterology. 2012; 143:951–962.e8.
Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med. 2013; 19:1438–1449.
Nakashima H, Nakamura M, Yamaguchi H, Yamanaka N, Akiyoshi T, Koga K, et al. Nuclear factor- B contributes to Hedgehog signaling pathway activation through Sonic Hedgehog induction in pancreatic cancer. Cancer Res. 2006; 66:7041–7049.
Kojima M, Morisaki T, Izuhara K, Uchiyama A, Matsunari Y, Katano M, et al. Lipopolysaccharide increases cyclo-oxygenase-2 expression in a colon carcinoma cell line through nuclear factor-κB activation. Oncogene. 2000; 19:1225–1231.
Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009; 19:156–172.
Cai SJ, Liu Y, Han S, Yang C. Brusatol, an NRF2 inhibitor for future cancer therapeutic. Cell Biosci. 2019; 9:45.
Sun X, Wang Q, Wang Y, Du L, Xu C, Liu Q. Brusatol enhances the radiosensitivity of A549 cells by promoting ROS production and enhancing DNA damage. Int J Mol Sci. 2016; 17:997.
Noorolyai S, Shajari N, Baghbani E, Sadreddini S, Baradaran B. The relation between PI3K/AKT signalling pathway and cancer. Gene. 2019; 698:120–128.
Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol. 2014; 24:R453–R462.
Li J, Zhou Y, Liu Y, Dai B, Zhang Y-H, Zhang P-F, Shi X-L. Sorafenib inhibits caspase-1 expression through suppressing TLR4/stat3/SUMO1 pathway in hepatocellular carcinoma. Cancer Biol Ther. 2018; 19:1057–1064.
Ding X, Li F, Zhang L. Knockdown of Delta-like 3 restricts lipopolysaccharide-induced inflammation, migration and invasion of A2058 melanoma cells via blocking Twist1-mediated epithelial-mesenchymal transition. Life Sci. 2019; 226:149–155.
Tavakolian S, Goudarzi H, Eslami G, Faghihloo E. Transcriptional regulation of epithelial to mesenchymal transition related genes by lipopolysaccharide in human cervical cancer cell line HeLa. Asian Pac J Cancer Prev. 2019; 20:2455–2461.
Vandooren J, Van den Steen PE, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol. 2013; 48:222–272.
Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem. 1994; 269:5241–5248.